87.51
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biontech
Its shares trade under the ticker BNTX. It has been listed since 10 October 2019. In the fiscal year to 31 December 2025, it reported revenue of €3.18bn and a net loss of €1.26bn. At that date it held total assets of €25.37bn and shareholders' equity of €22.18bn.
BioNTech SE operates as a clinical-stage biotechnology company. The company is headquartered in Mainz, Rheinland-Pfalz. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The company develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Oct 2019
- Employees
- 7,807
- Website
- biontech.de ↗
- Head office
- AN DER GOLDGRUBE 12, MAINZ, 2M, 55131
- Incorporated in
- 2M
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Helmut JeggleIndependent Chairman of the Supervisory Board, since 2008€288,000
- Prof. Ugur SahinChief Executive Officer, Member of the Management Board€5.4m
- Dr. Ulrich WandschneiderIndependent Deputy Chairman of the Supervisory Board, since 2018€157,000
- Mr. Ramon Zapata GomezChief Financial Officer
- Dr. Sierk PoettingChief Operating Officer, Member of the Management Board€2.6m
- Ms. Annemarie HanekampMember of the Management Board, Chief Commercial Officer€1.7m
- Mr. Ryan RichardsonChief Strategy Officer, Member of the Management Board€2.6m
- Mr. James RyanMember of the Management Board, Chief Legal Officer€881,000
- Dr. Oezlem TuereciChief Medical Office, Member of the Management Board€2.5m
- Prof. Anja MorawietzIndependent Member of the Supervisory Board€130,000
- Mr. Michael MotschmannIndependent Member of the Supervisory Board€100,000
- Prof. Rudolf StaudiglIndependent Member of the Supervisory Board€114,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 82
- Social
- 82
- Governance
- 82
- Direct emissions (scope 1)
- 1,342 t
- Energy emissions (scope 2)
- 8,785 t
- Value chain emissions (scope 3)
- 529,501 t
- Women in the workforce
- 51.6%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioNTech has a strong research and development team consisting of highly skilled scientists and experts in the field of biotechnology. This expertise enables the company to develop innovative solutions and make advancements in the biopharmaceutical industry.
- The company has established strategic partnerships with pharmaceutical giants such as Pfizer, which provides BioNTech with resources, distribution networks, and access to global markets. This collaboration leverages the strengths of both companies, leading to increased market presence and accelerated commercialization of products.
- BioNTech has successfully developed and gained regulatory approval for its mRNA-based COVID-19 vaccine, which has positioned the company as a key player in the fight against the pandemic. This breakthrough achievement has enhanced BioNTech's reputation and increased investor confidence in the company.
Weaknesses
- As a relatively young company, BioNTech has a limited product portfolio compared to established competitors in the industry. This narrow product range makes the company susceptible to market fluctuations and increased competition.
- BioNTech's reliance on external funding for its research and development activities poses a potential weakness. The company heavily depends on grants, collaborations, and partnerships, which may expose it to financial uncertainties and restricted control over decision-making processes.
Opportunities
- The growing demand for personalized medicine and advancements in mRNA technology present significant opportunities for BioNTech. The company can further explore and develop mRNA-based therapies for various diseases, expanding its product pipeline and addressing unmet medical needs.
- BioNTech can leverage its expertise in mRNA technology to collaborate with other pharmaceutical companies, universities, and research institutions. By entering into partnerships or licensing agreements, the company can access new markets, diversify its revenue streams, and accelerate the development of innovative therapies.
Threats
- Intense competition within the biopharmaceutical industry poses a threat to BioNTech. Established companies and emerging players are investing heavily in research and development, potentially leading to the introduction of competing products that could impact BioNTech's market share.
- The regulatory environment and potential changes in government policies related to healthcare and drug approvals could pose risks for BioNTech. Changes in regulations or delays in obtaining regulatory approvals may hinder the company's ability to bring its products to market in a timely manner.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.